(MENAFN- GlobeNewsWire - Nasdaq)
Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Phathom Pharmaceuticals, Inc. (“Phathom” or the“Company”) (NASDAQ: PHAT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Phathom investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : , to discuss their legal rights, or click here to join the case via . The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.
On August 2, 2022, Phathom disclosed that it had“detected trace levels of a nitrosamine in vonoprazan drug product in [its] post-approval testing as [it] prepared for commercial launch.” As a result, the Company planned to seek approval for additional testing methods and controls“to address this impurity prior to releasing [its] first vonoprazan-based products to the market.” The Company also stated that this will result in a delay of planned product launches.
On this news, Phathom's stock fell $2.61, or 28.8%, to close at $6.46 per share on August 2, 2022, thereby injuring investors.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Tags #Phathompharma $PHAT Class Action Related Links
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.